Neurohumoral stimulation in type-2-diabetes as an emerging disease concept

Cardiovascular Diabetology

Volumn 3, Issue , 2004, Pages

  Pliquett, R U ^a   Fasshauer, M ^a   Bluher M ^a   Paschke, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Diabetes mellitus; Hormones; Inflammation; Oxidative stress; Sympathetic nervous system

Indexed keywords

ADIPOKINETIC HORMONE; ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; NEUROHORMONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

AUTONOMIC NEUROPATHY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; GLUCOSE TRANSPORT; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC INNERVATION; SYMPATHETIC TONE;

EID: 2942549545     PISSN: 14752840     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2840-3-4     Document Type: Review

References (98)

1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
2. Isnard R, Pousset F, Trochu J, Chafirovskaia O, Carayon A, Golmard J, Lechat P, Thomas D, Bouhour J, Komajda M: Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000, 86:417-421.
3. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002, 105:2392-2397.
4. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC: Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992, 67:719-724.
5. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D: Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk In Communities study, 1987-1998. Circulation 2003, 107:2190-2195.
6. Lindholm LH, Ibsen H, Borch J, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S et al.: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002, 20:1879-1886.
7. Brenner BM, Cooper ME, de Z, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
8. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001. JAMA 2003, 289:76-79.
9. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O: Low Plasma Ghrelin Is Associated With Insulin Resistance, Hypertension, and the Prevalence of Type 2 Diabetes. Diabetes 2003, 52:2546-2553.
10. Muntzel MS, Anderson EA, Johnson AK, Mark AL: Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens 1995, 17:39-50.
11. Van De Borne P, Hausberg M, Hoffman RP, Mark AL, Anderson EA: Hyperinsulinemia produces cardiac vagal withdrawal and nonuniform sympathetic activation in normal subjects. Am J Physiol 1999, 276:R178-R183.
12. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. Circulation 2000, 101:676-681.
13. Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ: Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care 2002, 25:537-541.
14. Christ M, Bauersachs J, Liebetrau C, Heck M, Gunther A, Wehling M: Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 2002, 51:2648-2652.
15. Katsuragi I, Okeda T, Yoshimatsu H, Utsunomiya N, Ina K, Sakata T: Transplantation of normal islets into the portal vein of Otsuka Long Evans Tokushima Fatty rats prevents diabetic progression. Exp Biol Med 2001, 226:681-685.
16. Burke JP, Williams K, Narayan KM, Leibson C, Haffner SM, Stern MP: A population perspective on diabetes prevention: whom should we target for preventing weight gain? Diabetes Care 2003, 26:1999-2004.
17. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI: Receptormediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100:270-278.
18. Gudbjornsdottir S, Lonnroth P, Sverrisdottir YB, Wallin BG, Elam M: Sympathetic Nerve Activity and Insulin in Obese Normotensive and Hypertensive Men. Hypertension 1996, 27:276-280.
19. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M: Interactions between leptin and the human sympathetic nervous system. Hypertension 2003, 41:1072-1079.
20. Beltowski J, Wojcicka G, Jamroz A: Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003, 170:21-29.
21. Xiao E, Xia-Zhang L, Vulliemoz NR, Ferin M, Wardlaw SL: Leptin Modulates Inflammatory Cytokine and Neuroendocrine Responses to Endotoxin in the Primate. Endocrinology 2003, 144:4350-4353.
22. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ: Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003, 149:331-335.
23. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C et al.: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884-1888.
24. Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O, Taskinen MR, Jansson PA: Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003, 52:1182-1186.
25. Verma S, Li SH, Wang CH, Fedak PWM, Li RK, Weisel RD, Mickle DAG: Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction. Circulation 2003, 108:736-740.
26. Liu JL, Pliquett RU, Brewer E, Cornish KG, Shen YT, Zucker IH: Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1906-R1913.
27. Abu-Elheiga L, Oh W, Kordari P, Wakil SJ: Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. PNAS 2003, 100:10207-10212.
28. Wiesner TD, Bluher M, Windgassen M, Paschke R: Improvement of Insulin Sensitivity after Adrenalectomy in Patients with Pheochromocytoma. J Clin Endocrinol Metab 2003, 88:3632-3636.
29. Fasshauer M, Klein J, Kriauciunas KM, Ueki K, Benito M, Kahn CR: Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Mol Cell Biol 2001, 21:319-329.
30. Fasshauer M, Klein J, Ueki K, Kriauciunas KM, Benito M, White MF, Kahn CR: Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. J Biol Chem 2000, 275:25494-25501.
31. Klein J, Fasshauer M, Ito M, Lowell BB, Benito M, Kahn CR: beta(3)-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. J Biol Chem 1999, 274:34795-34802.
32. Fasshauer M, Klein J, Lossner U, Paschke R: Interleukin (IL)-6 mRNA Expression is Stimulated by Insulin, Isoproterenol, Tumour Necrosis Factor Alpha, Growth Hormone, and IL-6 in 3T3-L1 Adipocytes. Horm Metab Res 2003, 35:147-152.
33. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001, 507:142-146.
34. Kusunoki M, Oshida Y, Iguchi A, Iida T, Suga T, Funado T, Sato Y, Kato K, Sakamoto N: Influence of sympatho-adrenal system on insulin sensitivity using the euglycemic clamp technique. Diabetes Res Clin Pract 1992, 17:125-131.
35. Turtzo LC, Marx R, Lane MD: Cross-talk between sympathetic neurons and adipocytes in coculture. PNAS 2001, 98:12385-12390.
36. Jacob S, Balletshofer B, Henriksen EJ, Volk A, Mehnert B, Loblein K, Haring HU, Rett K: Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press 1999, 8:261-268.
37. Aizawa T, Ishizaka N, Usui S, Ohashi N, Ohno M, Nagai R: Angiotensin II and catecholamines increase plasma levels of 8-epi-prostaglandin F(2alpha) with different pressor dependencies in rats. Hypertension 2002, 39:149-154.
38. Schade R, Gohler K, Burger W, Hirschelmann R: Modulation of rat C-reactive protein serum level by dexamethasone and adrenaline - comparison with the response of alpha 2-acute phase globulin. Agents Actions 1987, 22:280-287.
39. Takahashi T, Anzai T, Yoshikawa T, Maekawa Y, Asakura Y, Satoh T, Mitamura H, Ogawa S: Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction - role of neurohormones and cytokines. In J Cardiol 2003, 88:257-265.
40. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
41. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
42. Esler M: Differentiation in the effects of the angiotensin II receptor blocker class on autonomic function. J Hypertens 2002, 20(Suppl 5):S13-S19.
43. Le M, Mimassi N, Lancien F, Mabin D, Boucher JM, Blanc JJ: Heart rate variability, a target for the effects of angiotensin II in the brain of the trout Oncorhynchus mykiss. Brain Res 2002, 947:34-40.
44. Sowers JR: Hypertension, Angiotensin II, and Oxidative Stress. N Engl J Med 2002, 346:1999-2001.
45. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M et al.: Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002, 40:872-879.
46. Kranzhofer R, Browatzki M, Schmidt J, Kubler W: Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999, 257:826-828.
47. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003, 42:905-910.
48. Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M: Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003, 169:155-158.
49. Hornig B, Kohler C, Schlink D, Tatge H, Drexler H: AT1-Receptor Antagonism Improves Endothelial Function in Coronary Artery Disease by a Bradykinin/B2-Receptor-Dependent Mechanism. Hypertension 2003, 41:1092-1095.
50. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42:76-81.
51. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
52. Haluzik M, Sindelka G, Widimsky J, Prazny M, Zelinka T, Skrha J: Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens 2002, 16:41-45.
53. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT: Aldosterone-Induced Inflammation in the Rat Heart : Role of Oxidative Stress. Am J Pathol 2002, 161:1773-1781.
54. Kurbanov RD, Eliseeva MR, Tursunov RR, Kurbanova DR, Zakirova FA: [Humoral markers of endothelial dysfunction in essential hypertension]. Kardiologiia 2003, 43:61-64.
55. Korkmaz ME, Muderrisoglu H, Ulucam M, Ozin B: Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol 2000, 86:649-653.
56. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M: Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003, 41:574-581.
57. Cardillo C, Campia U, Bryant MB, Panza JA: Increased Activity of Endogenous Endothelin in Patients With Type II Diabetes Mellitus. Circulation 2002, 106:1783.
58. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD: Endothelin Contributes to Basal Vascular Tone and Endothelial Dysfunction in Human Obesity and Type 2 Diabetes. Diabetes 2002, 51:3517-3523.
59. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H: Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000, 269:713-717.
60. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF: Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003, 107:1053-1058.
61. Browatzki M, Schmidt J, Kubler W, Kranzhofer R: Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 2000, 95:98-105.
62. Wilkes JJ, Hevener A, Olefsky J: Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes 2003, 52:1904-1909.
63. Hawkins MF, Avery DD: Effects of centrally-administered bombesin and adrenalectomy on behavioral thermoregulation and locomotor activity. Neuropharmacology 1983, 22:1249-1255.
64. Hucking K, Hamilton W, Ellmerer M, Bergman RN: Burst-like control of lipolysis by the sympathetic nervous system in vivo. J Clin Invest 2003, 111:257-264.
65. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC: Hypothesis: Betaadrenergic receptor blockers and weight gain: A systematic analysis. Hypertension 2001, 37:250-254.
66. Keijzers GB, De Galan BE, Tack CJ, Smits P: Caffeine Can Decrease Insulin Sensitivity in Humans. Diabetes Care 2002, 25:364.
67. Karlsson AK: Insulin resistance and sympathetic function in high spinal cord injury. Spinal Cord 1999, 37:494-500.
68. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS: Heart-Rate Recovery Immediately after Exercise as a Predictor of Mortality. N Engl J Med 1999, 341:1351-1357.
69. Lind L, Andren B: Heart rate recovery after exercise is related to the insulin resistance syndrome and heart rate variability in elderly men. Am Heart J 2002, 144:666-672.
70. Haenni A, Lithell H: Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999, 17(Suppl 3):S29-S35.
71. Monti LD, Barlassina C, Citterio L, Galluccio E, Berzuini C, Setola E, Valsecchi G, Lucotti P, Pozza G, Bernardinelli L et al.: Endothelial Nitric Oxide Synthase Polymorphisms Are Associated With Type 2 Diabetes and the Insulin Resistance Syndrome. Diabetes 2003, 52:1270.
72. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A: Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003, 21:379-386.
73. Pliquett RU, Cornish KG, Peuler JD, Zucker IH: Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003, 107:2493-2498.
74. De A, Schaan BD, Maeda CY, Dall A, Wichi RB, Irigoyen MC: Cardiovascular control in experimental diabetes. Braz J Med Biol Res 2002, 35:1091-1100.
75. Kay HH, Grindle KM, Magness RR: Ethanol exposure induces oxidative stress and impairs nitric oxide availability in the human placental villi: a possible mechanism of toxicity. Am J Obstet Gynecol 2000, 182:682-688.
76. Zhang J, Liu Y, Shi J, Larson DF, Watson RR: Side-stream cigarette smoke induces dose-response in systemic inflammatory cytokine production and oxidative stress. Exp Biol Med (Maywood) 2002, 227:823-829.
77. Hausberg M, Mark AL, Winniford MD, Brown RE, Somers VK: Sympathetic and vascular effects of short-term passive smoke exposure in healthy nonsmokers. Circulation 1997, 96:282-287.
78. Bennett AJ, Sponberg AC, Graham T, Suomi SJ, Higley JD, DePetrillo PB: Initial ethanol exposure results in decreased heart rate variability in ethanol-naive rhesus monkeys. Eur J Pharmacol 2001, 433:169-172.
79. Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Murashima S, Nakatani K, Yano Y, Adachi Y: Increased Oxidative Stress Is Associated With Serum Levels of Triglyceride, Insulin Resistance, and Hyperinsulinemia in Japanese Metabolically Obese, Normal-Weight Men. Diabetes Care 2004, 27:631-632.
80. Dalle D, Giustarini D, Colombo R, Rossi R, Milzani A: Protein carbonylation in human diseases. Trends Mol Med 2003, 9:169-176.
81. Tirosh A, Rudich A, Potashnik R, Bashan N: Oxidative stress impairs insulin but not platelet-derived growth factor signalling in 3T3-L1 adipocytes. Biochem J 2001, 355:757-763.
82. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106:2067-2072.
83. Frossi B, De C, Daniel KC, Rivera J, Pucillo C: Oxidative stress stimulates IL-4 and IL-6 production in mast cells by an APE/ Ref-1-dependent pathway. Eur J Immunol 2003, 33:2168-2177.
84. Girouard H, Chulak C, LeJossec M, Lamontagne D, De Champlain J: Chronic antioxidant treatment improves sympathetic functions and beta-adrenergic pathway in the spontaneously hypertensive rats. J Hypertens 2003, 21:179-188.
85. Nightingale AK, Blackman DJ, Field R, Glover NJ, Pegge N, Mumford C, Schmitt M, Ellis GR, Morris T, Frenneaux MP: Role of nitric oxide and oxidative stress in baroreceptor dysfunction in patients with chronic heart failure. Clin Sci (Lond) 2003, 104:529-535.
86. Pliquett RU, Cornish KG, Zucker IH: Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003, 95:700-704.
87. Maack C, Kartes T, Kilter H, Schafers HJ, Nickenig G, Bohm M, Laufs U: Oxygen Free Radical Release in Human Failing Myocardium Is Associated With Increased Activity of Rac1-GTPase and Represents a Target for Statin Treatment. Circulation 2003, 108:1567-1574.
88. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
89. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23-33.
90. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R: Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002, 39:135-141.
91. Yasunari K, Maeda K, Nakamura M, Yoshikawa J: Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002, 39:777-780.
92. Urbanski A, Schwarz T, Neuner P, Krutmann J, Kirnbauer R, Kock A, Luger TA: Ultraviolet light induces increased circulating interleukin-6 in humans. J Invest Dermatol 1990, 94:808-811.
93. Hruza LL, Pentland AP: Mechanisms of UV-induced inflammation. J Invest Dermatol 1993, 100:35S-41S.
94. Festa A, Hanley AJ, Tracy RP, Agostino R, Haffner SM: Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003, 108:1822-1830.
95. Festa A, Agostino R, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137.
96. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N: Elevated C-Reactive Protein Is a Risk Factor for the Development of Type 2 Diabetes in Japanese Americans. Diabetes Care 2003, 26:2754-2757.
97. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156:1070-1077.
98. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM et al.: Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419.